Compare Dyne Therapeutics Inc. Common Stock (DYN) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $72.00M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 39.7× KraneShares Electric Vehicles and Future Mobility's market cap, and KraneShares Electric Vehicles and Future Mobility is more actively traded (31,901 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and KraneShares Electric Vehicles and Future Mobility for 48 Days on average.
| DYN | KARS | |
|---|---|---|
Market Cap | $2.86B | $72.00M |
Volume | 3,341,579 | 31,901 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $38.01 |
52-Week Low | $14.60 | $26.72 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
